Merck Appoints Maya Martinez-Davis as Global Head of Oncology

18-Apr-2016 - Germany

Merck announces the appointment of Maya Martinez-Davis (46), as Global Head of oncology Franchise for its biopharma business. She will report to Rehan Verjee, Chief Marketing and Strategy Officer of Merck’s Healthcare business sector, and will be based in Billerica, Massachusetts, USA.

Merck KGaA

Maya Martinez-Davis

In her new role leading the Global Oncology Franchise, Martinez-Davis’ responsibilities will include defining integrated global oncology strategies, and delivery of therapeutic launches, starting with Avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck, and currently managed under a strategic alliance with Pfizer. The first potential commercial launch for Avelumab is expected in 2017.

Prior to joining Merck, Martinez-Davis was a senior executive with Pfizer for more than a decade, delivering on therapeutic area portfolio strategies, in-market growth strategies, and major launches. Prior to her tenure with Pfizer, she held senior-level and director-level positions with Aventis Pharma in oncology.

Martinez-Davis assumes the role of her predecessor, Andrew Schiermeier.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances